Mark Haemmerle
About Mark Haemmerle
Mark Haemmerle is the Director of Clinical Data Management at Bristol Myers Squibb in Princeton, New Jersey, with over 15 years of experience in the field.
Company
Mark Haemmerle currently works at Bristol Myers Squibb as the Director of Clinical Data Management in Princeton, New Jersey, United States. Prior to his current role, he held several positions within the company, steadily progressing from Protocol Data Manager to his current directorial role.
Title
Mark Haemmerle serves as the Director of Clinical Data Management at Bristol Myers Squibb. His extensive experience in clinical data management spans over 15 years, demonstrating a strong commitment to patient safety and public health.
Background
Mark Haemmerle has a robust career history in clinical data management. He began his career at RadPharm as an Assistant Manager and was promoted to Manager of Clinical Data Management. He later transitioned to Novartis, where he served as Senior Data Manager for 5 years before joining Bristol Myers Squibb in 2015. At Bristol Myers Squibb, he has held positions including Protocol Data Manager, Lead Clinical Data Reviewer, Associate Director, and now Director.
Education and Expertise
Mark Haemmerle studied at Rider University, where he earned a Bachelor of Science degree in Marketing and Advertising. His academic background, combined with over 15 years of practical experience in clinical data management, positions him as an expert in his field.
Achievements
Throughout his career, Mark Haemmerle has demonstrated a strong commitment to patient safety and public health. He administers three legacy Celgene REMS programs that include Elements to Assure Safe Use (ETASU). He ensures investigational medicines are provided equitably through Pre-Approval Access programs and works collaboratively with physicians to determine the best course of action for patients. Additionally, he supports the development of bioequivalent generic drugs and advocates for tiered pricing of HIV medicines to enhance global treatment access.